Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare Sarcomas Refractory or Resistant to Standard Therapy
Findings from the AcSé Pembrolizumab study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1538 results
Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously Untreated Advanced Non-Clear-Cell RCC
Findings from the KEYNOTE-B61 study
Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for BRAF Mutations Who Received Vemurafenib-Cobimetinib
Findings from a biomarker-driven phase II study
First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with Advanced NSCLC Who Are Ineligible for Platinum-Based Chemotherapy
Findings from the IPSOS study
EMA Recommends Extension of Therapeutic Indications for Tremelimumab
New indication concerns the treatment of metastatic NSCLC in combination with durvalumab and platinum-based chemotherapy
Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely Resected Merkel Cell Carcinoma
Findings from an interim analysis of ADMEC-O study
Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL Who Had Had Disease Progression During Previous Treatment with a Covalent BTK Inhibitor
Findings from the BRUIN study
Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line Treatment of EGFR-mutated Advanced NSCLC
Findings from the LASER301 study
Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate in First-Line Treatment of Cisplatin-Ineligible Patients with Advanced Urothelial Cancer
Findings from the EV-103 randomised Cohort K
EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan
New indication concerns the treatment of patients with advanced HR-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting
Perioperative Nivolumab Plus Chemotherapy Results in Higher pCR and Longer Survival in Patients with Resectable Stage IIIA or IIIB NSCLC
Findings from the NADIM II study
Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial, and Neurocognitive Outcomes for 17 Common Childhood Cancer Subtypes
A set of core outcomes developed by the International Childhood Cancer Outcome Project